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a b s t r a c t
With the current global inﬂuenza vaccine production capacity the large demand for vaccines in case
of a pandemic can only be fulﬁlled when antigen dose sparing strategies are employed. Here we used
a murine challenge model to evaluate the potential of GPI-0100, a semi-synthetic saponin derivative,
to serve as a dose-sparing adjuvant for inﬂuenza subunit vaccine. Balb/c mice were immunized with
different doses of A/PR8 (H1N1) subunit antigen alone or in combination with varying doses of GPI-0100.vailable online 18 January 2011
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The addition of GPI-0100 signiﬁcantly stimulated antibody and cellular immune responses, especially of
the Th1 phenotype. Furthermore, virus titers detected in the lungs of mice challenged one week after the
second immunization were signiﬁcantly reduced among the animals that received GPI-0100-adjuvanted
vaccines. Remarkably, adjuvantation of subunit vaccine with GPI-0100 allowed a 25-fold reduction in
hemagglutinin dose without compromising the protective potential of the vaccine.
© 2011 Elsevier Ltd. Open access under the Elsevier OA license.
ose-sparing
. Introduction
Inﬂuenza pandemics are caused by the introduction of new
nﬂuenza A virus subtypes in the human population. The viruses
ither circulated in animal reservoirs and enter the human
opulation by zoönotic infections or they emerged by genetic reas-
ortment between human and animal inﬂuenza A viruses [1]. The
irus causing the outbreak of pandemic inﬂuenza A (H1N1) 2009
as the result of a series of reassortments among H1N1 swine
nﬂuenza viruses, H1N1 avian inﬂuenza virus and H3N2 human
nﬂuenza virus [2,3]. The reassorted virus crossed the species bar-
ier from swine to humans and caused a severe disease outbreak
artially due to a substantial antigenic drift of the swine H1 as
ompared to the H1 in the earlier circulating epidemic H1N1 virus.
enerally, the human population is immunologically naïve to such
oönotic or reassorted strains. Accordingly, disease outbreaks usu-
lly affect large geographical areas involving many countries and
an result in severe morbidity and mortality [4,5].
∗ Corresponding author at:Department ofMedicalMicrobiology,MolecularVirol-
gy Section, University Medical Center Groningen, P.O. Box 30001, EB 88, 9700 RB
roningen, The Netherlands. Tel.: +31 50 3632714.
E-mail address: a.l.w.huckriede@med.umcg.nl (A. Huckriede).
1 Current address: Department of Rheumatology and Clinical Immunology, Uni-
ersity Medical Center, Groningen, The Netherlands.
264-410X © 2011 Elsevier Ltd. 
oi:10.1016/j.vaccine.2011.01.012
Open access under the Elsevier OA license.From both a public health and socio-economic point of view,
vaccination stands as the primary strategy for the prevention
and control of inﬂuenza virus infections [6]. Currently licensed
inﬂuenza virus vaccines consist of whole inactivated virus or puri-
ﬁed virus proteins derived from virus grown in embryonated
chicken eggs. The manufacturing process is time-consuming and
the production capacity is limited [7]. Incorporation of antigen-
sparing adjuvant(s) into vaccine formulations is considered a
promising solution for the supply problem, which is a serious con-
cern during a pandemic outbreak [7]. Moreover, such adjuvants are
required to stimulate protective antibody titers [8].
The bark extract of the Molina tree Quillaia saponaria con-
tains triterpene saponins which have powerful adjuvant activity.
In 1978, an enriched mixture of saponins called Quil A was iden-
tiﬁed and was used commercially in a veterinary foot-and-mouth
disease vaccine [9]. However, its toxicity excludes its use in human
vaccines. In order to lower the compound toxicity, immune-
stimulating complexes (ISCOMs) containing cholesterol, saponin,
phospholipid andviral envelopeproteinsweredeveloped. Lethality
studies in mice determined the lethal dose of ISCOM-incoporated
Quil A to be 10–50g [10]. In another approach to lower the adju-
vant’s toxicity, RP-HPLC was used to purify the components of
the heterogenous mixture of Quil A. Ten of the obtained fractions
showed a similar level of adjuvant activity as Quil A itself with
different levels of toxicity. Among those fractions, QS-21 (with
a lethal dose of 500g) had low toxicity and QS-7 showed no
lethality in the dose range studied. More recently, a novel semi-
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ynthetic saponin adjuvant called GPI-0100 has been developed
rom QS-7. Lethality studies in mice showed that GPI-0100 (with a
ethal dose of 5000g) is 10 times less toxic than QS21 and 100
imes less toxic than ISCOM-incorporated Quil A. In addition, it
hows increased stability in aqueous solution at physiological pH
11,12]. Preclinical studies of GPI-0100 adjuvant with ovalbumin
OVA), hemagglutinin B (HagB) antigen of Porphyromonas gingivalis
nd glycoprotein D (gD) of herpes simplex virus type-1 (HSV-1)
ave shown increased induction of antigen-speciﬁc antibodies in
ice with a particular enhancement of the IgG2a isotype [11–18].
n addition, GPI-0100 induces antigen-speciﬁc cellular immune
esponses exempliﬁed by lymphocyte proliferation, cytokine (IFN-
and IL-2) secretion and CTL responses [11,12,17]. Furthermore,
PI-0100-adjuvanted HSV vaccines protect mice from virus chal-
enge with signiﬁcant reductions in virus titers, infected (lesion)
reas and mortality rates [16].
Subunit inﬂuenza vaccines contain puriﬁed hemagglutinin anti-
enswithout thepresenceofnatural immunemodulators andoften
ossess comparitively modest immunogenicity. Here we evalu-
te the adjuvant activity of GPI-0100 for A/PR8 (H1N1) inﬂuenza
ubunit vaccine in mice. We show that inﬂuenza-speciﬁc immune
esponses are strongly boosted by low doses of GPI-0100 and that,
n the presence of GPI-0100, the antigen dose can be reduced sub-
tantiallywithout loss of protective efﬁcacy.We therefore consider
PI-0100 a promising candidate adjuvant for pandemic inﬂuenza
accines.
. Material and methods
.1. GPI-0100
GPI-0100 was provided by Hawaii Biotech, Inc. (Aiea, HI, U.S.A.)
s powder and was stored at 4 ◦C. A stock solution of GPI-0100
5mg/ml) was prepared in HNE buffer (5mM Hepes, 150mM NaCl
nd 0.1mM EDTA, pH 7.4). After centrifugation through a Spin-X
entrifuge tubeﬁlter (Corning, U.S.A.), the sterile stock solutionwas
tored at 4 ◦C for use within one month.
.2. Virus and subunit vaccine
A stock of A/PR8 (H1N1) inﬂuenza virus propagated on
adin–Darby canine kidney cells (MDCK) was kindly provided by
olvay Biologicals (Weesp, The Netherlands). The virus titer was
etermined by measuring the tissue culture infectious dose 50
TCID50). To this end serial twofold dilutions of virus suspension
ere inoculated on MDCK cells grown in serum-free medium. 1h
ater TPCK trypsin (Sigma, Zwijdrecht, Netherlands) was added to a
nal concentration of 7.5g/ml. After 72h, supernatants were col-
ected and transferred to a round-bottom 96-well plate followed
y the addition of 50l 1% guinea pig erythrocytes to each well.
he plate was incubated for 2h before reading. The titer was deter-
ined as the highest virus dilution at which hemagglutination was
isible and the TCID50 was calculated by the method of Reed and
uench [19].
For inactivation, the virus was incubated with freshly prepared
0% -propiolactone in citrate buffer (125mM sodium citrate,
50mM sodium chloride, pH 8.2) at a ﬁnal concentration of 0.1%
-propiolactone. Inactivation was carried out for 24h at 4 ◦C
nder continuous stirring. After inactivation, the viruswasdialyzed
gainst phosphate-buffered saline (PBS) overnight at 4 c. Subunit
accine was prepared by solubilizing the inactivated virus (0.8mg
irus protein/ml) in PBS containing Tween 80 (0.3mg/ml) and hex-
decyltrimethylammonium bromide (CTAB, 1.5mg/ml) for 3h at
◦C under continuous stirring, and removal of the viral nucle-
capsid from the preparation by ultracentrifugation for 30min(2011) 2037–2043
at 50,000 rpm in a TLA100.3 rotor at 4 c. Detergents were then
removed by overnight absorption onto Biobeads SM2 (634mg/ml,
Bio-Rad, Hercules, CA) washed with methanol prior to use.
Protein content of the inactivated virus and subunit material
was determined by a modiﬁed Lowry assay [20]. Hemagglutinin
(HA) content was assumed to be one third of the total protein for
whole inactivated virus (based on the known protein composition
of inﬂuenza virus and the molecular weight of the viral proteins)
and to be equal to the total protein for subunit material (based
on silver-stained SDS polyacrylamide gels run under reducing and
non-reducing condition) [21]. Vaccinesweremixedat the indicated
amounts of subunit and GPI-0100 just before immunization.
2.3. Animal handling
The protocol for the animal experiment described here was
approved by the Ethics Committee on Animal Research of the Uni-
versity of Groningen. Female Balb/cmice (Harlan, TheNetherlands)
aged 8–10 weeks were grouped (n=6 per group) and immunized
intramuscularly (i.m.) with A/PR/8 subunit vaccine with or with-
out GPI-0100 adjuvant in a two-dose immunization regimen (day
0 and day 20). Control mice were injected with HNE buffer. On day
27, mice were challenged intranasally with 1×104 TCID50 A/PR/8
inﬂuenza virus in 50l of HNE buffer. The virus challenge was car-
ried out under isoﬂurane anesthesia to ensure deposition of the
virus into the lungs.Miceweremonitored, twice a day at ﬁxed time
points, for clinical signs of illness including weight loss, changes in
behavior and appearance. Mice were bled and sacriﬁced on day 30.
Serum samples were collected for ELISA assay. Spleens were har-
vested and splenocyteswere used for ELISPOT assay. The lung lobes
were collected and stored in 1ml PBS in a −80 ◦C freezer for later
homogenization and lung virus titer detection.
2.4. IgG, IgG1 and IgG2a ELISAs
Inﬂuenza HA-speciﬁc antibody titers were determined by ELISA
[21]. Brieﬂy, ELISA plates (Greiner, Alphen a/d Rijn, Netherlands)
were coated with 0.2g of PR8 inﬂuenza subunit antigen per well.
Twofold serial dilutions of serum samples in PBST (0.05% Tween
20 in PBS) were applied to the wells in duplicate and incubated
for 1.5h. Horseradish peroxidase-conjugated goat antibody against
mouse IgG-isotypes (Southern Biotechnologies) was added for the
detection of bound H1N1-speciﬁc IgG, IgG1 or IgG2a antibodies.
All incubations were carried out at 37 ◦C. The staining was per-
formed with substrate buffer (50mM phosphate buffer, pH 5.5,
containing 0.04% o-phenylenediamine and 0.012% H2O2) and the
absorbance at 492nm (A492) was measured using an ELISA reader
(Bio-tek instruments, Inc., Vermont, U.S.A.). Titers (with the stan-
dard error of the means (S.E.M.)) are given as the 10log of the
reciprocal of the sample dilution calculated to correspond to an
A492 of 0.2. For calculation purposes, sera with titers below detec-
tion limit were assigned an arbitrary 10log titer corresponding to
half of the detection limit.
Calibration plates for IgG1 and IgG2a assay were coated with
0.1g goat anti-mouse IgG (Southern Biotechnologies). Increasing
concentrations of puriﬁed mouse IgG1 or IgG2a (Southern Biotech-
nologies) were added to the plates. Sample IgG1 and IgG2a titers
were expressed as concentrations (g/ml) of inﬂuenza HA-speciﬁc
IgG1 and IgG2a± S.E.M.
2.5. ELISPOTELISA plates were coated with puriﬁed rat IgG1 against mouse
IFN- or IL-4 (Pharmingen, San Diego, CA) [21]. Freshly isolated
splenocytes (500,000 cells per well) were added to the plates
in triplicate in medium containing 5% fetal calf serum with or
ne 29 (2011) 2037–2043 2039
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Fig. 1. Total IgG, IgG1 and IgG2a antibody responses one week after the second
immunization. Mice were vaccinated on day 0 and day 20 with 1g A/PR/8 subunit
vaccine without and with the indicated doses of GPI-0100 adjuvant. (A) Average
10log IgG titers± standard error of themean (S.E.M.),n=6mice per group. Thedetec-
tion limit of the assay is represented by the dotted line. (B, C) Average quantitiesH. Liu et al. / Vacci
ithout PR8 subunit (1g per well). After an overnight incuba-
ion at 37 ◦C, cells were lysed in ice-cold water and plates were
ashed. IFN- detection was carried out by 1h incubation with
iotinylated anti-mouse IFN- antibody followed by a subsequent
ncubation with streptavidin-alkaline phosphatase (Pharmingen)
or 1h. Spotswere developedby adding 100l of substrate solution
o each well. The substrate solution included 5-bromo-4-chloro-
-indolylphosphate in water containing 6mg/ml agarose (Sigma),
.2mg/ml 2-amino-2-methyl-1-propanol (Sigma) and 0.08l/ml
riton X-405 at 1mg/ml. The plates were further incubated for 3h
t 37 ◦C. Images of the plates were taken by an automated ELISA-
pot assay video analysis system (A EL VIS, Hannover, Germany).
pots were counted manually. Spots observed in the wells with-
ut PR8 subunit (backgrounds) were subtracted from the spots
bserved in the stimulated wells. Results are presented as num-
er of inﬂuenza-speciﬁc IFN-- or IL-4-secreting cells per 500,000
plenocytes.
.6. Determination of virus titers in lungs of challenged mice
Lungs collected from the challenged mice were homogenized
nd the supernatants of lung extracts were collected and stored
t −80 ◦C until use [21]. Virus titers were determined by inoculat-
ng serial dilutions of the supernatants on MDCK cells as described
bove (Section 2.2). The highest dilution that still resulted in
emagglutination was taken as the virus titer in the lungs. Results
re presented as 10log virus titer per gram of lung tissue.
.7. Statistical analysis
The unpaired Student’s t-test was used to determine if the dif-
erences in inﬂuenza-speciﬁc responses observed between groups
f mice were signiﬁcant. A p value of p<0.05 was considered sig-
iﬁcant.
. Results
.1. GPI-0100 boosts inﬂuenza-speciﬁc humoral immune
esponses in a dose-dependent manner
To elucidate the adjuvant activity of GPI-0100 on antibody
esponses elicited by inﬂuenza subunit vaccine, mice were immu-
ized twiceonday0andday20with1gHAwithdifferentdosesof
PI-0100 (15, 50 or 150g). Blood samples were taken one week
fter the second immunization for evaluation of total inﬂuenza-
peciﬁc IgG levels. The IgG levels were signiﬁcantly increased upon
PI-0100 adjuvantation in a dose-dependent manner (Fig. 1A,
< 0.0005 for all tested adjuvant doses). The enhancing effects
f GPI-0100 were observed for both IgG1 and IgG2a antibodies
Fig. 1B and C). In the group of mice receiving 1g unadjuvanted
A, inﬂuenza-speciﬁc IgG1 was found in all immunized mice but
iterswere low,while only 4 out of the 6mice developed detectable
gG2a titers. GPI-0100-adjuvanted HA induced detectable levels of
oth IgG subtypes in all immunizedmice in adose-dependentman-
er. (p≤0.001 for IgG1 and p<0.05 for IgG2a for all GPI-0100 doses
ested).
Spleens from the immunized mice were harvested and spleen
eights were determined (Fig. 2A). No changes in spleen weight
ere observed in mice receiving 15g GPI-0100-adjuvanted vac-
ines.However, signiﬁcant increments in spleenweightwere found
n mice receiving vaccine adjuvanted with 50g or more GPI-0100
p<0.005). For the follow-up study 30g GPI-0100 adjuvantation
as used with the aim of boosting sufﬁcient immune responses
ithout inducing splenomegaly. No signiﬁcant changes in spleen
eight were observed at this GPI-0100 dose (Fig. 2B).(g/ml) of IgG1 and IgG2a± S.E.M. Levels of signiﬁcance are depicted as follows:
*p<0.05, **p<0.005and ***p<0.0005,which refer to thedifferencesbetween immu-
nizations with and without GPI-0100.
3.2. GPI-0100-adjuvanted low-dose PR8 subunit vaccine induces
high inﬂuenza-speciﬁc humoral immune responses
To evaluate dose-sparing effects of GPI-0100, mice were immu-
nized twice with decreasing doses of A/PR/8 subunit vaccine (1, 0.2
and 0.04g HA) adjuvanted with 30g GPI-0100. Serum samples
were taken one week after the second immunization. None of the
mice receiving unadjuvanted 0.04g HA and only 2 out of 6 mice
receiving 0.2g HA developed detectable inﬂuenza-speciﬁc IgG
2040 H. Liu et al. / Vaccine 29 (2011) 2037–2043
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Fig. 2. Effect of GPI-0100 on the spleen weight of immunized mice. (A) Mice were
immunized with HNE buffer (circles) or 1g A/PR/8 subunit vaccine adjuvanted
with 15g (triangles), 50g (diamonds) or 150g (squares) GPI-0100. Spleens
were harvested and weighed one week after the second immunization. Spleen
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Fig. 3. Antigen dose-dependent pre-challenge IgG and post-challenge cytokine-
producing T cell responses. Mice were immunized on day 0 and on day 20 with
the indicated doses of A/PR/8 subunit vaccine without (white bars) or with (black
bars) 30g GPI-0100. (A) Sera were collected one week after the second immu-
nization. Average 10log IgG titers± S.E.M. are depicted (n=6 mice per group). The
detection limit of the assay is represented by the dotted line. (B, C) An intranasal
infection with 1×104 TCID50 live A/PR/8 virus was performed directly after serum
collection. Spleens were harvested three days after the virus challenge upon ter-eights of individualmice are depicted and the average per group is given as a black
ine. (B) Mice were immunizaed with HNE buffer (circles), unadjuvanted (open tri-
ngles) subunit vaccine, orwith 30gGPI-0100 adjuvant combinedwith 0.04, 0.2 or
g of antigen (ﬁlled triangles). Antigen dose itself had no effect on spleen weight.
iters (Fig. 3A). Unadjuvanted1gHA induced IgG in 5out of 6mice
ith an average titer of 3.31 10log.Vaccines adjuvanted with 30g
PI-0100 induced IgG titers in all vaccinated animals and these
ere signiﬁcantly higher than in the mice receiving unadjuvanted
accines (p<0.005 for all tested antigen doses.) Notably, IgG titers
chieved with adjuvanted low dose antigen (0.04g) were about
log higher than those achieved with non-adjuvanted high-dose
ntigen (1g).
The GPI-0100 adjuvant signiﬁcantly enhanced IgG1 titers at the
ow antigen doses (0.04 and 0.2gHA) and IgG2a titers at all tested
ntigen doses, respectively (Table 1, p<0.0001 (0.04g HA) and
0.0005 (0.2g HA) for IgG1 and <0.005 for IgG2a (all HA doses)).
otably, mice receiving low antigen doses (0.04 and 0.2g HA)
eveloped detectable IgG2a titers only in the presence of the GPI-
100 adjuvant. The adjuvant effects were especially pronounced
or low antigen doses.
.3. GPI-0100-adjuvanted low-dose PR8 subunit vaccine
nhances inﬂuenza-speciﬁc cellular immune responses
To evaluate adjuvant activity of GPI-0100 on cellular immune
esponses elicited by A/PR/8 subunit vaccine, ELISPOT assays were
erformed to detect inﬂuenza-speciﬁc cytokine-producing T cells
rom the immunized and challenged mice (Fig. 3B). No inﬂuenza-
peciﬁc IFN--producing T cells were found in control animals
njected with buffer and challenged with virus three days before
acriﬁce (data not shown). Unadjuvanted 0.04 and 0.2gHAbarely
nduced detectable inﬂuenza-speciﬁc IFN- responses. At a dose
f 1g, HA alone induced an average of 4 IFN--producing cellsmination. Splenocytes were isolated and stimulated overnight with PR8 subunit.
Average numbers of cytokine-producing splenocytes per 5×105 cells± S.E.M. are
depicted.
per 5×105 splenocytes in 3 out of 6 mice. GPI-0100 enhanced
the IFN- responses at all tested antigen doses. However, due
to the large variation in the number of IFN--producing T cells
within the experimental groups, signiﬁcance of the differences
between unadjuvanted and adjuvanted vaccines was achieved
H. Liu et al. / Vaccine 29 (2011) 2037–2043 2041
Table 1
Phenotype of the pre-challenge inﬂuenza-speciﬁc antibody responses.
g HA 30g
GPI-0100
Average inﬂuenza
HA-speciﬁc titer
(10log± S.E.M.)
IgG2a/IgG1±
S.E.M.a
IgG1 IgG2a
0.04
− 1.79 ± 0.09b N.D.c N.A.
+ 4.63 ± 0.14d 2.87 ± 0.30d 0.62 ± 0.06
0.20
− 2.51 ± 0.50e N.D.c N.A.
+ 4.80 ± 0.08d 3.63 ± 0.40d 0.76 ± 0.08
1.00
− 3.61 ± 0.28 2.10 ± 0.26e 0.59 ± 0.07
+ 4.48 ± 0.58f 3.56 ± 0.32d 0.87 ± 0.12
a Ratios were calculated per mouse. The average mean ratio and S.E.M. per exper-
imental group are presented.
b One out of six samples had a detectable serum antibody level. For calcula-
tion purposes, non-responding sera were assigned an arbitrary titer of 1.7 which
corresponds to half of the detection limit.
c Titer below detection limit.
d Signiﬁcantly higher than without GPI-0100 (p<0.05).
e Two out of six samples had a detectable serum antibody level. For calculation
purposes, non-responding sera were assigned an arbitrary titer of 1.7 as explained
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Fig. 4. Effects of unadjuvanted and GPI-0100-adjuvanted subunit vaccine on lung
virus titers. Mice described in the legend to Fig. 3, immunized with HNE buffer (cir-
cles), 0.04g (triangles), 0.2g (diamonds) or 1g (squares)A/PR/8 subunit vaccine
without (open symbols) or with (ﬁlled symbols) 30g GPI-0100 were infected with
live A/PR/8 virus 1 week after the second immunization. Lung samples were col-
lected three days later upon termination. Virus titer is expressed as the 10log virus
titer per gramof lung tissueof individualmice. Theblack line represents the geomet-
ric mean virus titer per group. Small stars indicate signiﬁcant differences betweennder footnoteb.
f One sample had a serum antibody level below the detection limit. For calcula-
ion purposes, the non-responding serum was assigned an arbitrary titer of 1.7 as
xplained under footnoteb.
nly for the animals that received 0.2g HA (p<0.05). Low num-
ers of inﬂuenza-speciﬁc IL-4-producing T cells were found three
ays after infection of control animals (data not shown). Simi-
ar low numbers were observed in mice immunized with 0.04g
nadjuvanted vaccines, but numbers increased in an antigen dose-
ependent manner (Fig. 3C). GPI-0100 induced an increase in the
umber of IL-4-producing cells at all tested antigen doses, yet
he difference was signiﬁcant only for the lowest antigen dose
p<0.05).
Thus, theGPI-0100 adjuvant enhanced the number of inﬂuenza-
peciﬁc cytokine-producing cells to a similar level at all antigen
oses tested. The effect of GPI-0100 on IFN- responses was
tronger than that on IL-4 responses. The phenotype of the cellular
mmune responses was further analyzed by calculating IFN-/IL-4
atios per individual mouse (Table 2). GPI-0100 adjuvantation did
ot change the Th2 dominance of the response to PR8 subunit vac-
ines, but signiﬁcantly enhanced Th1 responses leading to a more
alanced immune phenotype.
.4. GPI-0100 is required for lung protection against virus
hallenge at low antigen dose
Four weeks after the ﬁrst immunization mice were challenged
y intranasal administration of live A/PR/8 virus. During the ﬁrst
wo days after challenge little effect of the virus infection was seen.
y day three animals started to loose weight. This weight loss was
igher in the mice which had been immunized with adjuvanted
accines than in non-immunized mice and in mice which received
nadjuvanted vaccines. Weight loss correlated with the strength of
he induced immune responses but not with GPI-0100 dose. Three
able 2
henotype of the post-challenge inﬂuenza-speciﬁc cytokine responses.
g HA 30g GPI-0100 IFN-/IL-4± S.E.M.a
0.04
− 0.01 ± 0.01
+ 0.52 ± 0.36
0.20
− 0.01 ± 0.01
+ 0.21 ± 0.11
1.00
− 0.14 ± 0.12
+ 0.35 ± 0.22
a Ratios were calculated per mouse. The average mean ratio and S.E.M. per exper-
mental group are presented.mice receiving unadjuvanted and adjuvanted vaccine at the indicated antigen dose.
Large stars indicate signiﬁcant differences between immunized groups and the HNE
control group.
days after virus challenge, the animals were sacriﬁced and virus
titerswere determined in lung homogenates to evaluate protection
elicited by the vaccines. The HNE buffer group showed an average
lung virus titer of 6.45 10log (Fig. 4). The average titer in lungs of
mice receiving a low dose of unadjuvated HA (0.04 and 0.2g) was
not statistically different from that of the buffer group. Only mice
receiving 1g unadjuvanted HA showed a statistically signiﬁcant
reduction in lung virus titers (p<0.05). Immunization with GPI-
0100-adjuvanted vaccine resulted in signiﬁcantly decreased lung
virus titer at all tested antigen doses (p values between buffer and
the adjuvanted vaccines were ≤0.01 for all antigen doses tested, p
values betweenunadjuvanted and adjuvanted vaccineswere≤0.05
or ≤0.01, at HA doses of 1g or 0.04 and 0.2g, respectively). The
result shows that GPI-0100 improves vaccine-elicited protection
against inﬂuenza virus infection even at an extremely low antigen
dose of 0.04g HA.
4. Discussion
GPI-0100 is a stable semi-synthetic saponin derivative, which
has been demonstrated to stimulate both the humoral and the
cellular arm of the immune system [10–12,17,22]. In the present
study we evaluated the immunogenicity and protective efﬁcacy
of GPI-0100-adjuvanted A/PR8 inﬂuenza subunit vaccine in mice.
The results show that GPI-0100 boosts inﬂuenza-speciﬁc antibody
responses of the IgG1 and especially the IgG2a subtype in a dose-
dependentmanner. Therewas also a trend towardshighernumbers
of inﬂuenza-speciﬁc cytokine-producing T cells inmice immunized
with GPI-0100 adjuvanted vaccine though differences were not
signiﬁcant for all antigen doses studied. Furthermore, GPI-0100-
enhanced immune responses provided better protection against
inﬂuenza virus infection as demonstrated by reduced lung virus
titers after challenge. Remarkably, an adjuvanted 0.04g HA dose
presented a better formulation than an unadjuvanted 1g HA dose
for all immune parameters studied.
In line with earlier studies using OVA, HagB antigen of P. gin-
givalis and gD antigen of HSV-1, here we conﬁrm that GPI-0100
boosts antigen-speciﬁc antibody responses with a Th1 IgG isotype
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roﬁle in a dose-dependent manner [11,12,14,16]. High levels of
ntigen-speciﬁc IgG2a titerswere induced in addition to IgG1 titers,
esulting in a more balanced Th1/Th2 antibody response. In addi-
ion, we observed that GPI-0100 stimulates antigen-speciﬁc IFN-
esponses, which has also been reported previously in OVA stud-
es [11]. Structural analysis has identiﬁed the C4 aldehyde group
f GPI-0100 as a feature essential for inducing Th1 immunity. The
ldehyde group has been suggested to form an imino linkage with
mino groups on certain T cell surface receptors. This may gener-
te co-stimulatory signals similar to those provided by activated
ntigen-presenting cells [10,12].
In our study, the enhanced immunogenicity elicited by subunit
accine containing 50g or more GPI-0100 was accompanied by
pleen enlargement and increased spleen weights in vaccinated
ice. However, neither signiﬁcant increase in splenocyte num-
er nor any change in the relative frequency of B cells, CD4 and
D8 T cells was found. Therefore, it is unlikely that the observed
ffects are due to hyper immune-stimulation. Some saponin adju-
ants are known to possess an angiogenic effect and the spleen
nlargementmay thusbe causedby increasedblood supply [23,24].
arlier lethality studies and toxicology tests analyzing serum crea-
inine kinase (CK) and aspartate aminotransferase (AST) levels (as
ndicator for muscle and liver damage, respectively) showed that
PI-0100 under 1000g has little to no effect in mice, a species
eported to be sensitive to saponin compounds [10,12]. Moreover,
clinical studywithGPI-0100-adjuvanted prostate cancer vaccines
howed high induction of antigen-speciﬁc IgM and IgG (IgG1 and
gG3) titers in the cancer patients without serious side effects at an
juvant dose of 3000g [15].
Many adjuvants have been tested in animal models yet
luminum-based adjuvants have long been the only licensed
djuvants for use in human vaccines [25,26]. In recent years,
qualene-based adjuvants like MF59 and AS03 were also licensed
n Europe as adjuvants for inﬂuenza vaccines, and a vaccine against
uman papilloma virus containing monophosphoryl lipid (MPL)
was registered in the U.S. and around the world [27–29]. Clin-
cal trials with aluminum-based adjuvants in combination with
andemic inﬂuenza virus vaccines did not provide evidence for a
igniﬁcant immunostimulating effect of aluminum compounds on
nﬂuenza-speciﬁc responses [30–32]. On the other hand, MF59 and
S03 do enhance antibody responses to pandemic inﬂuenza virus
accines and allow antigen dose reduction [28,33–38]. An MF59-
djuvanted seasonal inﬂuenza vaccine is registered in Europe for
se in elderly. Moreover, MF59 and AS03 were both used as adju-
ants forH1N1vaccinesduring the2009A/H1N1pandemic.Clinical
rials on MPLA-adjuvanted inﬂuenza virus vaccines are yet to be
one.
In our experiments, GPI-0100 enhanced inﬂuenza-speciﬁc IgG
iters to A/PR/8 subunit vaccine by a factor of 30-230 with the
reatest enhancement seen at low antigen doses. Moreover, GPI-
100 adjuvantation especially stimulated Th1-related immune
esponses (IgG2a and IFN--producing T cells) and signiﬁcantly
mproved the protective potential of inﬂuenza subunit vaccine. In
ontrast, adjuvantation with aluminum hydroxide enhanced the
gG titer to A/PR8 subunit vaccine by a factor of 15 but increased
ainly antibodies of the IgG1 subtype and did not improve pro-
ection against challenge with live virus [21]. Mouse studies have
hown that the MF59 adjuvant can stimulate inﬂuenza-speciﬁc IgG
iters up to 120-fold [27,39,40]. The enhancements were observed
n both IgG1 and IgG2a subtypes, with a bias to IgG1, and cor-
elated with better lung protection. AS03-adjuvanted inﬂuenza
accines have been studied in ferrets but no data in mice are
vailable for comparison [41]. Thus, with respect to enhance-
ent of antibody titers (at least in mice) GPI-0100 performs as
ell or better as adjuvants currently used in clinical inﬂuenza
accines.
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Despite the boosting effects on humoral immune responses,
both aluminum-based adjuvants and MF59 have minimal effects
on antigen-speciﬁc IFN- production and cellular immunogenicity,
which are important in controlling inﬂuenza virus in the lungs and
are crucial for immune memory formation and long-term vaccine
protection [21,39,42–44]. GPI-0100, on the other hand, does show
adjuvant effects on cellular immunogenicity especially on IFN--
but also on IL-4-responses.
In conclusion, we show that GPI-0100 has the capacity to
function as a potent adjuvant for inﬂuenza subunit vaccines. In
the murine model system the immune-enhancing effects of GPI-
0100 are stronger than those observed in previous studies using
aluminum-based adjuvants or MF59 [21,27,39,40]. Furthermore,
GPI-0100 boosts both Th1 (IgG2a and IFN-) and Th2 (IgG1 and IL-
4) responses. Th1 responses are particularly stimulated resulting
in skewing to a desirable immune phenotype that leads to bet-
ter protection against inﬂuenza virus infection [21,45,46]. Notably,
whenadjuvantedwithGPI-0100, a very lowdose of subunit vaccine
(0.04g HA) remains immunogenic and provides protection from
virus growth in the lungs. In order to achieve a similar level of pro-
tection 1g unadjuvanted HA, a 25-fold higher dose, was required.
Therefore, GPI-0100 is a promising candidate adjuvant for stimu-
lating inﬂuenza-speciﬁc immune responses and for antigen sparing
in case of an inﬂuenza pandemic.
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